Skip to content

Efficacy and safety of T cell vaccination in the treatment of immune rejection of allogenic skin transplantation .

Efficacy and safety of T cell vaccination in the treatment of immune rejection of allogenic skin transplantation .

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR1800016738
Enrollment
Unknown
Registered
2018-06-21
Start date
2018-07-01
Completion date
Unknown
Last updated
2018-06-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Immunological rejection of allogenic skin transplantation

Interventions

case series:T cell vaccination

Sponsors

Shenzhen Ruipuxun Academy for Stem Cell & Regenerative Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
6 Years to 60 Years

Inclusion criteria

Inclusion criteria: 1. Aged 6-60 years old; 2. Patient with autologous skin deficiency needs allogeneic skin to cover wounds; 3. Good function situation of immportant organs; 4. No systemic infection; 5. Non tumor patient; 6. Patient with a history of anaphylaxis; 7. Patient without immunodeficiency disease; 8. Having signed informed consent papers; 9. Patient and family members agree to cooperate follow-up with good compliance.

Exclusion criteria

Exclusion criteria: 1. Skin trauma with other complex visceral injuries; 2. Severe large area burns with multiple organ failure; 3. Patients who need skin grafts and have sufficient syngeneic donors; 4. Cancer patients; 5. Patients with autoimmune deficiency or other acquired,congenital immunodeficiency diseases; 6. Patients with a history of allergy; 7. Patients with long-term use of hormones and immunosuppressive agents; 8. Pregnant or lactating women; 9. Participated in clinical trials of other drugs within one month; 10.History of Organ Transplantation; 11.According to the investigator's judgment, there are serious concomitant diseases that endanger the patient's safety or affect the patient's completion of the study; 12. Patients who did not sign informed consent;

Design outcomes

Primary

MeasureTime frame
Graft Survival Time;Histology;CD4+ T cells;CD8+ T cells;Regulatory T cells;CD28+ T cells;Bilirubin;Glutamic-Pyruvic Transaminase;CRP;Neutrophil count;

Countries

China

Contacts

Public ContactZhao Zhenlin

Shenzhen Ruipuxun Academy for Stem Cell & Regenerative Medicine

zhaozl2006@163.com+86 13828895409

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026